Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2023
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 09 Nov 2021 Results of post-hoc subgroup analysis assessing whether MetS status affected efficacy and safety of tildrakizumab presented at the ACR Convergence 2021
- 13 May 2021 Results published in the Annals of the Rheumatic Diseases
- 31 Oct 2020 According to a Sun Pharmaceutical Industries media release, data from this study was presented at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.